AbbVie Maintains US Humira Erosion Belief As 2023 Negotiations Near
Originator Has Previously Outlined 45% Erosion ‘Plus-Or-Minus 10%’
Executive Summary
AbbVie is not yet changing its modelling for Humira’s erosion in 2023, when as many as nine competing biosimilars could launch. The originator stated however that it will be in a better position to comment when it “goes through negotiations this summer” with payers and insurance providers.
You may also be interested in...
FTC Urged To Investigate AbbVie’s IP Strategy On Humira
AbbVie delayed biosimilar competition to Humira “for far longer than warranted” and may have “engaged in other anti-competitive conduct to maintain its market share and pricing power” for the adalimumab brand, according to members of the US House of Representatives’ committee on oversight and reform. The US Federal Trade Commission has been urged to open a formal inquiry into the originator’s conduct.
Apotex Moves First On Combigan As US Patent Expiry Looms
Apotex has moved first on Allergan’s Combigan, introducing a US authorized generic as the clock ticks on the originator’s IP. Sandoz is among ANDA sponsors seemingly waiting for patent protection to lapse.
Teva: $420m Securities Settlement In Our ‘Best Interest’
Teva has commented on its proposed settlement of $420m with a class of investors following allegations that the firm had concealed the true nature of its increase in profits, which artificially inflated the price of Teva’s securities.